Alexandria Real Estate Equities, Inc. Elects Claire Aldridge, PhD, to Board of Directors
Rhea-AI Summary
Alexandria Real Estate Equities (NYSE: ARE) has elected Claire Aldridge, PhD, to its Board of Directors, effective March 14, 2025. Dr. Aldridge will serve as a member of the Life Science Committee, with her term running until the company's 2025 annual meeting.
Dr. Aldridge brings over 25 years of experience in biotechnology, venture capital, entrepreneurship, and AI-accelerated therapeutic development. She previously served as chief strategy officer at Form Bio, where she led AI and machine learning integration for genomic analysis. Her prior roles include senior positions at Taysha Gene Therapies, UT Southwestern Medical Center, and Remeditex Ventures.
Currently, she serves on multiple boards including Colossal Biosciences' scientific advisory board and 4E Therapeutics' board of directors. She was recognized as one of Forbes' 10 women leading the synthetic biology revolution in April 2023.
Positive
- Board strengthened with 25+ years life science industry expertise
- Addition of AI and machine learning expertise in genomic analysis
- Enhanced biotechnology and venture capital experience on board
- Independent director appointment improving corporate governance
Negative
- None.
News Market Reaction – ARE
On the day this news was published, ARE declined 2.34%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
"Dr. Aldridge's distinguished career in the life science industry spans more than 25 years across biotechnology, venture capital, entrepreneurship, technology commercialization and AI-accelerated therapeutic development," said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. "Her deep business and scientific experience, which includes facilitating the translation of scientific discoveries into innovative therapies that improve patient lives, will further bolster the combined expertise of our board, and we are honored to welcome her."
Dr. Aldridge was the chief strategy officer of Form Bio, the first spinout from the de-extinction and biodiversity company Colossal Biosciences. At Form Bio, Dr. Aldridge led the integration of artificial intelligence and machine learning into genomic analysis and advanced therapeutics programs, such as gene therapy, biological sequence alignment and directed evolution, to accelerate the development of safe and effective new medicines. She also oversaw the generation of vast proprietary datasets needed to train sophisticated AI models. Prior to Form Bio, Dr. Aldridge served as senior vice president, chief of staff and business operations at Taysha Gene Therapies, a clinical-stage biotechnology company focused on advancing gene therapies for severe monogenic diseases of the central nervous system. She was previously associate vice president of commercialization and business development at UT Southwestern Medical Center and vice president of venture development at Remeditex Ventures.
Dr. Aldridge currently serves on the scientific advisory board of Colossal Biosciences and on the board of directors of 4E Therapeutics. She is also a member of the Product Development Advisory Committee of the Cancer Prevention and Research Institute of
Dr. Aldridge received her PhD from Duke University in the Department of Immunology and the Program in Genetics and Genomics and her Bachelor of Science degree in Biomedical Science from Texas A&M University.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the potential impacts of a director's appointment to the company's board of directors and expectations regarding the company's performance and success. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.
CONTACT: Sara Kabakoff, Senior Vice President – Chief Content Officer, (626) 788-5578, skabakoff@are.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-elects-claire-aldridge-phd-to-board-of-directors-302393735.html
SOURCE Alexandria Real Estate Equities, Inc.
FAQ
When will Claire Aldridge join Alexandria Real Estate Equities (ARE) board of directors?
What committees will Dr. Aldridge serve on ARE's board?
What is Dr. Aldridge's background in life sciences?
What are Dr. Aldridge's current board positions besides ARE?
